VSM Wealth Advisory’s Sagimet Biosciences SGMT Stock Holding History

VSM Wealth Advisory’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,500	Closed	-$8.88K	–	514
2025 Q4	$8.88K	Buy	+1,500	New	+$10.8K	﹤0.01%	342

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VSM Wealth Advisory's SGMT Position: Q1 2026 in Review

VSM Wealth Advisory sold out of Sagimet Biosciences (SGMT) in Q1 2026, closing a stake of 1,500 shares — an estimated $8.88K sold.

VSM Wealth Advisory first reported a position in SGMT in Q4 2025 and held it in 1 quarter. The position peaked at $8.88K in Q4 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

VSM Wealth Advisory reported no remaining Sagimet Biosciences position as of Q1 2026 after selling out during the quarter.
VSM Wealth Advisory sold 1,500 Sagimet Biosciences shares in Q1 2026, an estimated $8.88K.
VSM Wealth Advisory first reported a position in Sagimet Biosciences in Q4 2025 and held it in 1 quarter.
VSM Wealth Advisory's Sagimet Biosciences position peaked at $8.88K in Q4 2025.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on VSM Wealth Advisory's 13F filing for Q1 2026, filed 6 May 2026.